Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 1992-01-06 (34 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: VERDUN (55100), Meuse
PHARMACIE TOGNOLI-POIRAT : revenue, balance sheet and financial ratios
PHARMACIE TOGNOLI-POIRAT is a French company
founded 34 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in VERDUN (55100),
this company of category PME
shows in 2024 a revenue of 1.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE TOGNOLI-POIRAT (SIREN 384126165)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
1 447 198 €
1 415 483 €
1 500 524 €
1 440 597 €
1 319 270 €
N/C
N/C
1 147 247 €
N/C
Net income
38 440 €
62 922 €
83 588 €
68 656 €
53 133 €
78 897 €
48 750 €
34 579 €
50 160 €
EBITDA
51 038 €
64 990 €
107 274 €
88 733 €
61 107 €
N/C
N/C
58 275 €
N/C
Net margin
2.7%
4.4%
5.6%
4.8%
4.0%
N/C
N/C
3.0%
N/C
Revenue and income statement
In 2024, PHARMACIE TOGNOLI-POIRAT achieves revenue of 1.4 M€. Revenue is growing positively over 9 years (CAGR: +3.4%). Vs 2023: +2%. After deducting consumption (992 k€), gross margin stands at 455 k€, i.e. a rate of 31%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 51 k€, representing 3.5% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 38 k€, i.e. 2.7% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2024)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
1 447 198 €
Gross margin (2024)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
454 945 €
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
51 038 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
50 084 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
38 440 €
EBITDA margin (2024)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
3.5%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 10%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.3 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 2.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
10.241%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
76.638%
Cash flow / Revenue (2024)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
2.175%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
2.307
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
8.502
9.955
8.767
12.221
10.075
10.477
7.368
8.331
10.241
Financial autonomy
75.911
73.588
76.405
73.239
74.354
75.604
75.678
75.727
76.638
Repayment capacity
None
1.119
None
None
1.571
1.105
0.636
1.281
2.307
Cash flow / Revenue
None%
4.573%
None%
None%
3.082%
4.321%
5.389%
3.288%
2.175%
Sector positioning
Debt ratio
10.242024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Excellent
In 2024, the debt ratio of PHARMACIE TOGNOLI-POIRAT (10.24) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
76.64%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent
In 2024, the financial autonomy of PHARMACIE TOGNOLI-POIRAT (76.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
2.31 years2024
2022
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Good+17 pts over 3 years
In 2024, the repayment capacity of PHARMACIE TOGNOLI-POIRAT (2.31) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 223.93. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.1x. Operating income very largely covers interest expenses: high safety margin.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
223.929
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
111.6
122.219
133.214
167.432
164.144
189.685
186.185
200.604
223.929
Interest coverage
None
2.653
None
None
0.982
0.613
0.988
4.268
6.123
Sector positioning
Liquidity ratio
223.932024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Good+19 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE TOGNOLI-POIRAT (223.93) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
6.12x2024
2022
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Good+39 pts over 3 years
In 2024, the interest coverage of PHARMACIE TOGNOLI-POIRAT (6.1x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 12 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 37 days. Favorable situation: supplier credit is longer than customer credit by 25 days. Inventory turnover is 22 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 38 days of revenue, i.e. 154 k€ to permanently finance.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
154 112 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
12 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
37 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
22 j
WCR in days of revenue (2024)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
38 j
WCR and payment terms evolution PHARMACIE TOGNOLI-POIRAT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
121 539 €
0 €
0 €
104 895 €
99 790 €
126 389 €
129 814 €
154 112 €
Inventory turnover (days)
0
22
0
0
19
18
19
19
22
Customer payment term (days)
0
15
0
0
10
7
9
8
12
Supplier payment term (days)
0
51
0
0
43
40
50
50
37
Positioning of PHARMACIE TOGNOLI-POIRAT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE TOGNOLI-POIRAT is estimated at
620 709 €
(range 461 905€ - 876 910€).
With an EBITDA of 51 038€, the sector multiple of 9.2x is applied.
The price/revenue ratio is 0.64x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
461k€620k€876k€
620 709 €Range: 461 905€ - 876 910€
NAF 5 année 2024
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
51 038 €×9.2x
Estimation471 309 €
308 728€ - 732 788€
Revenue Multiple30%
1 447 198 €×0.64x
Estimation925 749 €
775 993€ - 1 166 483€
Net Income Multiple20%
38 440 €×14.0x
Estimation536 651 €
373 715€ - 802 860€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE TOGNOLI-POIRAT with other companies in the same sector:
Frequently asked questions about PHARMACIE TOGNOLI-POIRAT
What is the revenue of PHARMACIE TOGNOLI-POIRAT ?
The revenue of PHARMACIE TOGNOLI-POIRAT in 2024 is 1.4 M€.
Is PHARMACIE TOGNOLI-POIRAT profitable?
Yes, PHARMACIE TOGNOLI-POIRAT generated a net profit of 38 k€ in 2024.
Where is the headquarters of PHARMACIE TOGNOLI-POIRAT ?
The headquarters of PHARMACIE TOGNOLI-POIRAT is located in VERDUN (55100), in the department Meuse.
Where to find the tax return of PHARMACIE TOGNOLI-POIRAT ?
The tax return of PHARMACIE TOGNOLI-POIRAT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE TOGNOLI-POIRAT operate?
PHARMACIE TOGNOLI-POIRAT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart